Key Takeaways
- Record quarter, scale inflection: Standalone PAT in Q2 alone matched the entire Q1 standalone EBITDA, a milestone management used to illustrate the operating leverage now kicking in.
- Standalone margin surge to 35%: Execution of production orders lifted standalone EBITDA margin 900 bps YoY and 400 bps QoQ, though management cautioned that quarterly mix-driven swings of a few hundred bps are normal.
- IDL drag persists, turnaround deferred: The explosives subsidiary remained loss-making in a seasonally lean quarter; management declined to share capex or turnaround specifics and said improvement will take "a couple of quarters more."
- Order book poised to more than double: The current ~₹1,765 cr book is expected to reach ₹4,500–5,000 cr by March, contingent on the MIGM order landing by February.
- What to watch next quarter: Whether the MIGM order actually arrives by February, the pace of IDL’s promised improvement, and any confirmation that H2 revenue is tracking toward the ₹700+ cr target.
The MIGM Order: The Quarter’s Defining Binary
- Sole-source, trials done, waiting on paperwork: All user trials are complete and Apollo is the sole source for electronic processing systems and sensors; no second vendor exists, so future production orders will also go only to Apollo.
- RFQ expected November, order by February: The Indian Navy plans to release the purchase order before January/February, with a 20% advance payment provision to be released before the financial year-end.
- Order book transformation: Once placed, MIGM alone is expected to lift the order book from ~₹1,765 cr to ₹4,500–5,000 cr, with an execution window of two and a half years versus the typical 18 months for new orders.
- Delay risk is acknowledged but contained: Even if the order slips by a month or two, management says business momentum will continue because the current order book and proprietary supplier orders from existing customers provide a buffer.
Karunakar Reddy Baddam: "There are so many strategic programs are there, where nuclear-warhead and all will be there. We are not supposed to talk about such programs. So many programs are going on, okay? So not just Pinaka and all, only two, three programs only people knows, public knows, general public. But several other programs also are going on."
Revenue Growth: H1 Misses the Run-Rate, Full-Year Guide Holds
- H1 standalone revenue grew ~30%, below the 45–50% earlier guide: Management attributed the gap to timing and maintained the full-year standalone growth guidance of 35–45%, citing increased capacity from Unit 3 phase 1 and the existing order base.
- H2 must deliver over ₹700 cr to catch up: Management is targeting 35–45% more execution in H2 versus H1; per an analyst’s math, H2 FY26 was ~₹400 cr, so the implied ask is a sharp step-up.
- Production cycle time is a self-inflicted bottleneck being fixed: Qualification testing currently depends on third-party and DRDO facilities, causing waits of weeks or months; in-house EMC, navigation, and calibration test facilities are being installed and expected to be operational in one month, which should materially reduce production time.
- Unit 3 is the growth enabler: The first phase is now operational; once fully live by March 2027, the facility will be almost 12 times bigger than the present one and is expected to support scaled-up revenues for five to six years.
Krishna Sai Kumar Addepalli: "In Q1 FY27, our EBITDA excluding other income was INR48 crore. In Q2 FY27, our PAT alone was INR48 crore. What we earned at the operating level a quarter ago, we now delivered at the bottom line. That is the scale delivered with the discipline."
Margin Dynamics: Production Mix Lifts, Tax Rate Bites
- Standalone EBITDA margin hit 35% in Q2, up 900 bps YoY: The jump was driven by execution of "decently good production orders" versus lower-margin development projects, a mix shift management warned can reverse quarter-to-quarter and should not be read as an annuity run-rate.
- Consolidated margin also improved: Q2 consolidated EBITDA margin reached 28.6% versus ~25.8% in H1, again attributed to product mix variation.
- Tax rate spike to ~51% on standalone: Because standalone turnover crossed ₹400 cr in FY24-25, the applicable income tax rate shifted from 25% to 30% under rules effective this year, sharply compressing the PAT conversion from the EBITDA jump.
- Cash flow inflection is years away: Positive operating cash flow on an annual basis, with quarter-on-quarter positivity, is expected only from FY29 onwards, when the order mix shifts to majority production orders from the current tilt toward development projects.
The Missile & Weapons Pipeline: Breadth Beyond the Headlines
- Pinaka: The MoD is releasing orders for ~2,000 rockets to 2–3 companies; Apollo has submitted its RFQ for 300 numbers under the MIL case, with orders expected before December-end. Separately, Apollo is in the race for the 120-km variant’s DCPP production partnership, which is not yet finalized.
- Heavyweight torpedo: The Indian Navy has raised an RFQ to BDL for 30 units on fast-track, with the order expected to be finalized in November and delivery within nine months; a subsequent order for ~125 units is in the pipeline, and a larger advanced heavyweight torpedo volume order is expected in FY28.
- QRSAM: The MoD plans to split the missile order 50% to BDL and 50% to private industry; Apollo Group is in the race for the private portion, noting that most onboard systems are done by Apollo and propulsion by Premier. For subsystems where no second vendor exists, Apollo expects nomination-basis orders.
- Varunastra: Apollo expects a ₹100 cr+ order from BDL’s recent ₹1,700 cr torpedo order.
- Pralay and competitive weapon manufacturing: Apollo is participating as one of the companies for complete missile production, currently at the RFQ stage, and is shortlisted for competitive weapon manufacturing across 8–9 programs where technology transfer is being offered.
Karunakar Reddy Baddam: "Most of the things in QRSAM, most of the onboard systems Apollo is doing, and the propulsion side, Premier is doing. If anybody wants to see the major portion of the weapon, the Apollo Group only is doing. I am sure MoD wants to consider two private industries. I am sure that we also will be there in this thing."
Group Structure & Ambition: Shauryastra, Premier, and the ₹25,000 cr Target
- Shauryastra Defense System launched: A new associate company with Apollo holding a 34% stake, led by Dr. VK Saraswat (former DRDO Chairman), will design and develop complete weapon systems and longer-range platforms (300 km, 500 km, 900 km) in areas where DRDO is not active. Shauryastra handles development, Apollo handles production, and IP is held jointly.
- Premier Explosives acquisition progressing: CCI approval is in hand, clearing the way for the open offer; once completed, Apollo will be positioned to address the complete missile ecosystem (electronics, mechanical, propulsion, rocket motors). Management declined to comment on Premier’s order inflows or the 155mm shell order status until the process closes.
- IDL expansion plans are large but opaque: Management disclosed plans for 15 types of manufacturing plants and a big investment raise, plus the acquisition of 2,000 more acres near Hyderabad (adding to 1,200 already held), but declined to share capex figures or a detailed turnaround plan on this call.
- MD’s aspirational group target: ₹25,000 cr in five years: The target spans the total group of companies and was reiterated on the call, though it carries no timeline condition beyond the five-year horizon and no breakdown by entity.
- Global OEM ambition in five to six years: Management framed the strategy as emerging as a global OEM through partnerships and collaboration with Indian industry players rather than direct competition, aiming to build cost-competitive systems for the armed forces.
Karunakar Reddy Baddam: "See, entry barrier for the new companies coming into this business, one has to understand the quality standards of the defense. And overnight getting into this business is not that easy. ... At least in my this thing, I can say at least four or five years' time it will take for anybody getting into defense business."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Standalone revenue growth | 35–45% YoY growth | FY27 full year |
| MIGM order receipt | Purchase order from Indian Navy, with 20% advance payment provision | By February, not exceeding March FY27 |
| Order book expansion | Grow from ~₹1,765 cr to ₹4,500–5,000 cr | By March FY27, contingent on MIGM order placement |
| Pinaka subsystem order | RFQ submitted for 300 numbers under MIL case | Orders expected maximum before December-end |
| Heavyweight torpedo order | 30-unit emergency order via BDL | Order finalization expected November; delivery within 9 months |
| In-house test facilities | EMC, navigation, and calibration systems operational | Within one month |
| Unit 3 full operational readiness | Facility supporting scaled-up revenues for 5–6 years | Going live by March 2027 |
| Positive operating cash flow | Annual and quarter-on-quarter positive OCF | From FY29 onwards |
| Consolidated guidance (including Premier, IDL) | Energetics business guidance to be provided | Post-acquisition completion, expected in ~1 month |
| IDL turnaround | Improvement in overall performance | "A couple of quarters more" |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Consolidated revenue | ₹388 cr, up 72% YoY and 54% QoQ, all-time high |
| Consolidated EBITDA excl. other income | ₹111 cr, up 88% YoY and 107% QoQ, all-time high |
| Consolidated EBITDA margin excl. other income | 29%, expanded 200 bps YoY and 700 bps QoQ, all-time high |
| Consolidated PAT | ₹46 cr, up 40% YoY and 83% QoQ, all-time high |
| Standalone revenue | ₹306 cr, up 36% YoY and 96% QoQ, all-time high |
| Standalone EBITDA excl. other income | ₹108 cr, up 82% YoY and 122% QoQ, record |
| Standalone EBITDA margin | 35%, up 900 bps YoY and 400 bps QoQ |
| Standalone PAT | ₹48 cr, up 46% YoY and 73% QoQ, record |
| Standalone gross margin | ~40% (per an analyst's math) |
| H1 FY27 consolidated revenue | ₹639 cr, up 78% YoY, record |
| H1 FY27 consolidated EBITDA excl. other income | ₹165 cr, up 65% YoY, record |
| H1 FY27 consolidated PAT | ₹71 cr, up 50% YoY, record |
| H1 FY27 standalone revenue | ₹462 cr, up 29% YoY, record |
| H1 FY27 standalone EBITDA margin | 34%, expanded 600 bps, all-time high |
| H1 FY27 standalone PAT margin | 16%, expanded 200 bps, all-time high |
| Order book | ₹1,765 cr as of Sep 30, 2026, all-time high; standalone portion a little less than ₹1,300 cr |
| Order book expected by FY27 end | ₹4,500 cr to ₹5,000 cr, once MIGM order is placed |
| Revenue growth guidance | 35% to 45% for FY27 |
| Working capital days | 353 days, improved from 359 in FY26 |
| Cash flow from operations (H1 FY27) | ₹22 cr positive |
| R&D expense | ~8% of revenue |
| Effective tax rate (standalone Q2) | ~51%, due to shift from 25% to 30% tax rate under old regime |
| Production capacity expansion | ~12x of present facility; Unit 3 phase one operational, full completion by Mar 2027 |
| Positive operating cash flow (annual) | Expected from FY29 onwards |
| Shauryastra stake | 33% held by Apollo, later corrected to 34% by management |